
Arrowhead Pharmaceuticals Reports Positive Cardiometabolic Data at EAS 2026
Arrowhead Pharmaceuticals Unveils Encouraging Clinical Cardiometabolic Findings at the 94th European Atherosclerosis Society Congress Arrowhead Pharmaceuticals has presented new clinical findings supporting the broader use of plozasiran, its investigational small…












